[go: up one dir, main page]

MX2018005097A - Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5. - Google Patents

Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.

Info

Publication number
MX2018005097A
MX2018005097A MX2018005097A MX2018005097A MX2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A
Authority
MX
Mexico
Prior art keywords
death
receiver
join
death receiver
highly powerful
Prior art date
Application number
MX2018005097A
Other languages
English (en)
Other versions
MX391162B (es
Inventor
Vasquez Maximiliano
Wang Lihong
Zhang April
Jin Kim Kyung
Ding Yi
Park Hangil
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of MX2018005097A publication Critical patent/MX2018005097A/es
Publication of MX391162B publication Critical patent/MX391162B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales que se unen al receptor de muerte 4 y al receptor de muerte 5, a una composición farmacéutica que comprende los mismos, y a métodos de tratamiento que comprenden administrar esta composición farmacéutica a un paciente.
MX2018005097A 2015-10-30 2016-10-28 Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5 MX391162B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248782P 2015-10-30 2015-10-30
PCT/US2016/059517 WO2017075484A2 (en) 2015-10-30 2016-10-28 Highly potent antibodies binding to death receptor 4 and death receptor 5

Publications (2)

Publication Number Publication Date
MX2018005097A true MX2018005097A (es) 2019-05-16
MX391162B MX391162B (es) 2025-03-21

Family

ID=58630890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005097A MX391162B (es) 2015-10-30 2016-10-28 Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
MX2022000317A MX2022000317A (es) 2015-10-30 2018-04-25 Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000317A MX2022000317A (es) 2015-10-30 2018-04-25 Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.

Country Status (9)

Country Link
US (2) US10941204B2 (es)
EP (1) EP3368076B1 (es)
JP (2) JP6869553B2 (es)
KR (1) KR102791773B1 (es)
CN (2) CN109195626B (es)
CA (1) CA3003033A1 (es)
ES (1) ES3026760T3 (es)
MX (2) MX391162B (es)
WO (1) WO2017075484A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195626B (zh) 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
KR20230116833A (ko) * 2020-11-25 2023-08-04 더 호스피탈 포 식 칠드런 Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
JP2005168497A (ja) * 2001-05-18 2005-06-30 Kirin Brewery Co Ltd 抗ｔｒａｉｌ−ｒ抗体およびその用途
ATE433996T1 (de) * 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
CN103755807A (zh) 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
BR112013005116A2 (pt) * 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
PL2636736T3 (pl) * 2010-10-29 2016-09-30 Nowe przeciwciało anty-dr5
FR2967676B1 (fr) * 2010-11-19 2014-09-19 Agronomique Inst Nat Rech Ligand d'hormone luteinisante et complexe ligand-gonadotrophine
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
DK3150632T3 (en) 2011-06-10 2020-04-27 Canada Minister Nat Defence ANTI-RICIN ANTIBODIES AND APPLICATIONS THEREOF
JP2015524821A (ja) 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
CN104245736B (zh) * 2012-10-26 2016-12-21 和元生物技术（上海）股份有限公司 抗人死亡受体5胞外区的人源化单克隆抗体
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
SG11201609912TA (en) * 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2016122702A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
CN109195626B (zh) 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体

Also Published As

Publication number Publication date
US10941204B2 (en) 2021-03-09
WO2017075484A2 (en) 2017-05-04
US20190062443A1 (en) 2019-02-28
JP2021104050A (ja) 2021-07-26
EP3368076A2 (en) 2018-09-05
KR20180069066A (ko) 2018-06-22
KR102791773B1 (ko) 2025-04-03
MX2022000317A (es) 2022-02-10
JP6869553B2 (ja) 2021-05-12
US20210238297A1 (en) 2021-08-05
EP3368076C0 (en) 2025-04-30
EP3368076B1 (en) 2025-04-30
MX391162B (es) 2025-03-21
US11891446B2 (en) 2024-02-06
CN109195626B (zh) 2022-09-13
CN116333125A (zh) 2023-06-27
WO2017075484A3 (en) 2017-06-22
JP2019502653A (ja) 2019-01-31
JP7036471B2 (ja) 2022-03-15
EP3368076A4 (en) 2019-08-28
ES3026760T3 (en) 2025-06-12
CA3003033A1 (en) 2017-05-04
CN109195626A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201891299A1 (ru) Терапевтические антитела к cd9
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
EA201692560A1 (ru) Моноклональные антитела против эпитопа her2 и способы их применения